| 4SC AG |
Haemostatix Ltd |
| Abingworth Management Limited |
HBM Partners AG |
| Action Pharma A/S |
HealthCap |
| Adamant Ventures |
Helsinn Healthcare SA |
| Aescap Venture |
Helvea SA |
| Affimed Therapeutics AG |
Hybrigenics SA |
| AGF Private Equity |
Immune Targeting Systems Ltd |
| Akers Biosciences, Inc. |
Immunocore Ltd. |
| Algeta ASA |
Inno Bio Ventures Sdn Bhd |
| Alta Partners |
InnovationsKapital |
| AM-Pharma B.V. |
INVEST SECURITIES |
| Andhra Jyothy |
Katan Associates |
| Antisoma Research Ltd |
Kresta, Schnider & Partners AG |
| Aravis Venture Associates AG |
Kuros ApS |
| Ascent Therapeutics, Inc. |
Le Temps |
| Atlas Venture |
Lilly |
| Avir Green Hills Biotechnology AG |
LSP |
| Axentis Pharma AG |
Lumavita AG |
| Axxam SpA |
Mellitech |
| Baigo Capital GmbH |
Merck & Co. |
| Bank Sarasin & Cie AG |
Merck Serono International S.A. |
| Bay City Capital LLC |
Merck Serono SA |
| Bayhill Therapeutics, Inc. |
Microbiochips |
| BB Biotech Ventures |
MicroDiscovery GmbH |
| Biocrates Life Sciences GmbH |
MPM Capital |
| BioMedPartners |
N.M Rothschild & Sons Ltd |
| Bionest |
Nature Biotechnology |
| BioScience Managers Limited |
NGN Capital LLC |
| Biotec Pharmacon AS |
Nomura Code Securities |
| biotech.com |
Novartis International AG |
| Biotie Therapies Corp. |
Novartis Vaccines & Diagnostics |
| BioTOP Berlin-Brandenburg |
Objective Capital |
| Breslin AG |
OctoPlus N.V. |
| Bridgehead International |
Onelife Advisors SA |
| Bristol-Myers Squib |
PharmaVentures Ltd. |
| caprotec bioanalytics GmbH |
PharmaWave Ltd |
| Cellerix SA |
Phytopharm Plc |
| Cerimon Pharmaceuticals, Inc. |
ProBioGen AG |
| Clavis Pharma ASA |
Quest Management NV |
| Clinuvel |
Revotar Biopharmaceuticals AG |
| College Hill |
Roche Venture Fund |
| Covagen AG |
Sal. Oppenheim Jr. & Cie |
| Credit Suisse |
Santaris Pharma A/S |
| CureVac GmbH |
Sensimed AG |
| Cylene Pharmaceuticals, Inc. |
Seventure Partners |
| CytRx Corporation |
Shire Pharmaceuticals Group plc |
| Deloitte AG |
Siegfried Biologics |
| Deutsche Bank AG |
Sigma-Tau Pharma Ltd. |
| DeveloGen AG |
Silence Therapeutics plc |
| DnB NOR Asset Management |
SIX Swiss Exchange AG |
| Dow Jones |
Staatz Business Development & Strategy |
| DyoDelta Biosciences |
Synosia Therapeutics |
| Eclosion |
TcLand Expression SA |
| Edmond de Rothschild Investment Partners |
Thiakis Limited |
| Elm Biotech |
TiGenix NV |
| ENDOCELLS |
TPG Biotech/TPG Growth |
| EnVivo Pharmaceuticals, Inc. |
UCB-Pharma AG |
| Equity Development Ltd. |
Uniobioscreen SA |
| ERYtech Pharma |
Venture Valuation AG |
| ESBATech AG |
Vesalius Biocapital |
| Esteve Group |
Warburg Pincus LLC |
| e-Therapeutics |
Werder Consulting |
| ETV Capital |
Wilex AG |
| European Investment Fund |
WntResearch |
| EVA - the Basel life sciences start-up agency |
Xeno Medical, Ltd |
| Evolva SA |
Xention Ltd. |
| Evotec AG |
Zürcher Kantonalbank |
| Excellentia Global Partners |
|
| F. Hoffmann-La Roche Ltd |
|
| Ferghana Partners |
|
| Forbion Capital Partners |
|
| Galantos Pharma GmbH |
|
| Gilde Investment Management B.V. |
|
| GiMV NV |
|
| GlaxoSmithKline |
|
| Global Life Science Ventures |
|
| Global Life Science Ventures AG |
|
| Grace Advisory |
|